The pharmacokinetics of Sch 34343, a new broad-spectrum penem antibiotic, was studied in subjects receiving 1 g of "C-labeled drug by intravenous administration. At the end of a 30-min intravenous infusion, the mean maximum concentration of drug in serum was 39 ,ug/ml for unchanged Sch 34343 and 49 ,ueq/ml for total radioactivity. The mean serum half-lives of Sch 34343 were 0.16 h for the distribution phase and 0.80 h for the elimination phase. The total body clearance of Sch 34343 was 7.52 ml/min per kg, and the mean apparent volume of distribution was 525 ml/kg. Over a 4-day period, mean urinary excretion of radioactivity accounted for 87.9% of the dose, and mean urinary excretion of unchanged Sch 34343 accounted for 23.6% of the dose. The total radioactivity in feces on days 0 to 6 accounted for only 0. % of the dose. In serum from 0.5 and 1 h, unchanged Sch 34343 represented the major radioactive peak, with negligible amounts of several metabolites. In urine, there were at least six metabolites in addition to Sch 34343. The amount of unchanged Sch 34343 accounted for 33% of radioactivity in samples of urine from 0 to 2 h, 22% in urine from 2 to 4 h, 15% in urine from 4 to 8 h, and 0% in urine from 8 to 12 h., Sch 34343 is a new broad-spectrum penem antibiotic. It has excellent activity against gram-positive (MIC, <0.18 ,ug/ml) and gram-negative (MIC, <2 jig/ml) organisms except pseudomonads. Its activity against anaerobes (MIC, <0.1 ,ug/ml) is 20 to 40 times greater than that of either cefoxitin or moxalactam (1).
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The pharmacokinetics of ['4C]Sch 34343 has been extensively studied in rats and dogs (4) . After intravenous dosing, the elimination half-life (tl/2p) was 7 min in rats and 25 to 32 min in dogs. Sch 34343 was excreted rapidly and primarily into the urine in both species. Urinary excretion of total radioactivity ranged from 84 to 93%, and that of intact Sch 34343 ranged from 41 to 51% of the dose. This paper describes the pharmacokinetics of Sch 34343 in subjects receiving a-1-g dose by a 30-min intravenous infusion. The which retained Sch 34343, while most other components were eluted to waste. By using the column-switching technique, the Sch 34343 was eluted by a second solvent (10% acetonitrile in acetate buffer, 0.01 M, pH 3.8) onto an analytical column (25 by 0.46 cm; C18 MicroBondapak; Waters) for further separation and detection. The method provided good sensitivity (0.1 pug/ml), which was quite specific for Sch 34343 since related compounds and several potentially coadministered drugs did not interfere with Sch 34343 measurement. Serum containing 50, 10, 2, and 0.5 pig of Sch 34343 per ml resulted in mean observed concentrations of 49.5, 9.7, 1.8, and 0.49 ig/ml, respectively. In each case the coefficient of variation was less than 7%, demonstrating excellent reproducibility of the method.
Semipreparative HPLC procedure for studying the metabolic profile in serum and urine. Serum or urine samples were filtered through a 0.45-[Lm-pore filter (Acrodisc; Gelman Sciences, Inc., Ann Arbor, Mich.). Serum filtrate (2 ml) or urine filtrate (1 ml) was injected into the HPLC through a loop injector.
An HPLC was equipped with an A pump (model 6000; Waters) and a stainless steel partisil M-9 10/50 ODS3 column (Whatman, Inc., Clifton, N.J. ,ug * h/ml, and the AUCO-. for serum Sch 34343 was 29.24
,ug * h/ml ( Table 1) .
Concentrations of radioactivity in erythrocytes. Figure 2 illustrates the radioactivity levels in erythrocytes. The curves for erythrocyte radioactivity and serum radioactivity suggested similar t1/23 for radioactivity in serum and erythrocytes. In general, the radioactivity levels in erythrocytes were about one-fifth of those in serum.
Excretion of radioactivity in urine and feces and Sch 34343 in urine. The cumulative excretion data for radioactivity in urine and feces are shown in Table 2 . These data demonstrate that the radioactivity was excreted primarily into the urine. Over the 96-h period, a total of 87.9% of the dose was excreted in the urine, and only 0.8% of the dose was excreted in the feces. The total recovery of radioactivity in urine and feces, from 0 to 96 h after drug administration, accounted for 88.7% of the dose.
Most of the unchanged Sch 34343 in urine was excreted in the first 2 h after drug administration. Over a 12-h period, urinary excretion of Sch 34343 accounted for 23.6% of the dose. The apparent volume of distribution was calculated to be 525 ml/kg or 52.5% of the body weight. This suggests that Sch 34343 may be distributed into other tissue compartments in addition to plasma.
After the administration of [14CJSch 34343, the radioactivity was excreted primarily into the urine (87.9% of dose). Biliary excretion of the drug was negligible, since radioactivity in feces accounted for only 0.8% of the intravenous dose. However, it is not known whether Sch 34343 was reabsorbed in the gastrointestinal tract. Urinary excretion of unchanged Sch 34343 accounted for 23.6% of dose, similar to that for FCE-22891 (29%) (Perrone et al., 25th ICAAC) and imipenem (14 to 30%) (6) .
The ratio of unchanged Sch 34343 to total radioactivity in urine was 0.33 in 0-to 2-h urine, 0.22 in 2-to 4-h urine, 0.15 in 4-to 8-h urine, and 0 in 8-to 12-h urine. This rapid decrease in the ratio suggests rapid and extensive metabolism of Sch 34343 in humans after intravenous administration. This is in good agreement with results indicating the AUCO for serum radioactivity was about three times the AUCOCO for serum Sch 34343.
It has been reported that the bulk of metabolic inactivation of imipenem resulted from the hydrolysis of the beta-lactam ring by the renal dehydropeptidase I, a mammalian enzyme exhibiting beta-lactamase activity (3). Similar to imipenem, Sch 34343 also has a beta-lactam ring in its molecule and is susceptible to renal dehydropeptidase I. However, ringopened metabolites of Sch 34343 have not yet been identified. In the present study, we showed that after intravenous administration of Sch 34343, at least six metabolites (A1, A2, B, C, D, and E) were present in human urine. To elucidate the metabolic fate of Sch 34343 in humans, further work on identification of metabolites is needed.
